Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Polyclonal Treg Therapy in Cutaneous Lupus
NCT02428309Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2015
- Primary completion
- Sep 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLBS03 in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Significant Adverse Events at Week 48. Started Aug 2015; status: terminated.
02
Drugs
CLBS03
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02428309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428309.